
|Articles|March 31, 2023
Recommendations for Accelerating Cell and Gene Therapies
Author(s)Cognizant
While there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
President Trump Announces Nine More TrumpRx Participants
2
Eli Lilly Announces Topline Results From Phase III Trial Studying Oral GLP-1 Therapy Orforglipron
3
Pfizer’s Stock Reacts to Decreases in 2026 Revenue Projections in Full-Year 2026 Guidance Release
4
BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics
5